预约演示
更新于：2026-04-03
Mometasone Furoate
糠酸莫米松
更新于：2026-04-03
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
303
项与 糠酸莫米松 相关的临床试验ChiCTR2600116535
A single-blind, single-center clinical study evaluating the efficacy of layered selective laser combined with mometasone ointment in the treatment of melasma
CTIS2024-514003-33-00
Randomised phase III, partly blinded study comparing the efficacy and safety of clobetasol, mometasone and tacrolimus in the treatment of lichen sclerosus of the vulva in a paediatric population.
ChiCTR2500112481
A prospective, randomized, controlled study comparing the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in the treatment of moderate to severe allergic rhinitis symptoms
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
1,666
项与 糠酸莫米松 相关的文献（医药）2026-05-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Quaternized chitosan-coated liposomes enable pH-independent nasal mucoadhesion and a sustained local depot for mometasone furoate
Article
作者: Dong, Yipeng ; Wang, Yanjiao ; Jiang, Mai ; Zhang, Yu ; Yuan, Haoyang ; Tang, Xing ; He, Haibing ; Gou, Jingxin ; Yin, Tian ; Zhang, Wen
Limited nasal deposition and rapid clearance compromise the effectiveness of intranasal therapy for allergic rhinitis. Quaternized chitosan (QCS), which carries a permanent positive charge at the near-neutral pH of the nasal cavity, overcomes the pH-dependent limitations of conventional chitosan coatings. In this study, quaternized chitosan-modified liposomes encapsulating mometasone furoate (QCS-MF-Lip) were developed to enhance mucoadhesion and establish a local drug depot. The optimized formulation exhibited a small particle size (170 ± 1 nm) with a narrow size distribution (PDI 0.232 ± 0.011). QCS-MF-Lip showed a 5.26-fold higher mucin-binding affinity and approximately 4.7-fold greater ex vivo mucosal retention (19.59 ± 0.62 μg·cm⁻2) compared with unmodified liposomes and the commercial spray Nasonex®, respectively. In a rat model of allergic rhinitis, QCS-MF-Lip significantly alleviated symptoms and demonstrated superior therapeutic efficacy relative to Nasonex®, as reflected by reduced histamine levels and enhanced anti-inflammatory effects. These results suggest that permanently cationic QCS is a promising strategy for pH-independent nasal mucoadhesion and the establishment of a local intranasal drug depot.
2026-03-01JAMA Pediatrics
Intranasal Treatments for Children With Sleep-Disordered Breathing
Article
作者: Grobler, Anneke C. ; Vandeleur, Moya ; Davidson, Andrew ; Baker, Alice ; Perrett, Kirsten P. ; Pinczower, Gideon ; Rimmer, Joanne ; Nixon, Gillian M. ; Griffiths, Amanda ; Simpson, Catherine M. ; Anderson, Deborah ; Selman, Chris J. ; Rose, Elizabeth
Importance:
Symptoms of obstructive sleep apnea are common in childhood and associated with significant comorbidity. Surgical treatment with adenotonsillectomy is first-line treatment but medical treatments show potential to improve symptoms and reduce the need for surgery.
Objective:
To determine the efficacy of 6 weeks of intranasal steroid (INS) compared with saline in children with obstructive sleep-disordered breathing (OSDB) with persistent symptoms after a 6-week intranasal saline run-in.
Design, Setting, and Participants:
This was a double-blind, placebo-controlled, randomized clinical trial involving specialist clinic waitlists at 2 sites in Australia. Included were children aged 3 to 12 years. Study data were analyzed from January to June 2025.
Interventions:
All children received once-daily intranasal saline for 6 weeks (run-in). Those with persisting symptoms (SDB score ≥−1) were randomized to either once-daily intranasal mometasone furoate, 50 µg, (INS) or continued saline for a further 6 weeks.
Main Outcomes and Measures:
The primary outcome was symptom resolution (SDB score <−1). Secondary outcomes included behavior, quality of life, and parental perception of need for surgery. Analyses were adjusted for site and baseline measures.
Results:
A total of 150 children (mean [SD] age, 6.2 [2.3] years; 93 male [62%]) were recruited. Of 139 children who completed the run-in phase, 41 (29.5%) had symptom resolution after saline run-in. Among 93 children randomized to intervention groups (47 INS; 46 saline), symptom resolution occurred in 35.6% (95% CI, 22.9%-50.6%) and 36.4% (95% CI, 23.5%-51.6%) of the INS and saline group, respectively, with no evidence for a clinically significant difference between groups (risk difference, −0.9%; 95% CI, −20.7% to 19.0%;
P
= .93). No group differences were found in secondary outcomes. Subgroup analysis did not reveal a group more or less likely to respond to medical treatment.
Conclusions and Relevance:
Results of this randomized clinical trial show that 6 weeks of intranasal saline resolved OSDB symptoms in nearly one-third of children. An additional 6-week course of INS or saline led to resolution in another one-third (total resolution around 50%), with no added benefit from INS. Intranasal saline is an effective short-term first-line treatment for OSDB before consideration of polysomnography or surgical intervention. Results suggest that saline should be recommended for 3 months before assessing the need for specialist referral.
Trial Registration:
ClinicalTrials.gov Identifier:
NCT05382494
2026-03-01INTERNATIONAL IMMUNOPHARMACOLOGY
Umbilical cord mesenchymal stem cell-derived exosomes delivered via a thermosensitive hydrogel ameliorate atopic dermatitis by mitigating keratinocyte mitochondrial damage through activating the Wnt/β-catenin pathway
Article
作者: Dong, Yue ; Wu, Yi ; Shi, Chunrui ; Zhao, Xueping ; Zhang, Yue
Atopic dermatitis (AD) is a chronic inflammatory skin condition with a high global prevalence and a multifactorial etiology. Its development is primarily attributed to defective skin barrier function, immune dysregulation, and oxidative stress-induced impairments in mitochondrial activity within keratinocytes. While mesenchymal stem cell-derived exosomes show promise as a cell-free therapy, their limited efficacy via traditional systemic administration is a major challenge. To address this, we developed a thermosensitive poloxamer hydrogel-based system for the local delivery of human umbilical cord mesenchymal stem cell-derived exosomes(hUCMSC-exo). Our in vitro studies demonstrated that hUCMSC-exo were effectively internalized by HaCaT keratinocytes, significantly mitigating inflammatory responses, abnormal differentiation, and mitochondrial damage caused by IL-4/TNF-α. Through RNA-seq and mechanistic validation, we found that hUCMSC-exo exert their protective effects by activating the Wnt/β-catenin signaling pathway, which repairs the skin barrier and reduces oxidative stress. We successfully prepared and characterized the hydrogel, confirming its excellent biocompatibility and sustained-release properties. In a MC903-induced AD mouse model, local administration of the hUCMSC-exo hydrogel significantly improved AD-like symptoms and lowered serum IgE and Th2 cytokine levels. Compared to the topical steroid mometasone furoate, our formulation demonstrated comparable efficacy with a superior safety profile. Our study is the first to combine a thermosensitive hydrogel with hUCMSC-exo for local delivery, providing a safe and effective new therapeutic strategy for AD.
475
项与 糠酸莫米松 相关的新闻（医药）2026-04-02
·石药集团
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 瘙痒（皮肤发痒） | 巴西 | 2003-08-28 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 奥地利 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 捷克 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 波兰 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 西班牙 | 2022-01-27 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 季节性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 150 | Intranasal mometasone furoate | 鏇顧齋艱廠範鹹顧鑰糧(鬱網鑰鬱齋鹽蓋廠繭繭) = 觸遞齋廠憲壓鹹觸鹽網 願觸鏇遞鏇鹹獵壓製廠 (蓋糧觸積憲衊夢醖齋鹽, 22.9 ~ 50.6) | 不佳 | 2026-03-01 | ||
Saline | 鏇顧齋艱廠範鹹顧鑰糧(鬱網鑰鬱齋鹽蓋廠繭繭) = 顧廠網憲繭鹹憲觸繭鹹 願觸鏇遞鏇鹹獵壓製廠 (蓋糧觸積憲衊夢醖齋鹽, 23.5 ~ 51.6) | ||||||
临床3期 | 182 | Background therapy+LYR-210 (LYR-210) | 鹹鏇醖廠簾簾觸鏇夢選(顧醖憲淵齋衊構糧艱齋) = 醖淵壓壓鹽廠壓繭廠築 鬱襯齋艱餘蓋簾願蓋製 (鬱鑰鹽艱範夢遞艱鏇獵, 0.239) 更多 | - | 2026-02-19 | ||
Background therapy (Sham Procedure Control) | 鹹鏇醖廠簾簾觸鏇夢選(顧醖憲淵齋衊構糧艱齋) = 醖製膚憲窪憲鹽構憲憲 鬱襯齋艱餘蓋簾願蓋製 (鬱鑰鹽艱範夢遞艱鏇獵, 0.332) 更多 | ||||||
临床2期 | 59 | ESO-101 800 µg | 襯淵淵醖鬱範鹹蓋襯遞(蓋淵構蓋簾夢鹽衊製窪) = 膚遞範廠糧繭製夢鑰壓 膚鹽壓範簾夢簾餘廠夢 (艱襯艱淵廠衊獵憲艱鹹, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 襯淵淵醖鬱範鹹蓋襯遞(蓋淵構蓋簾夢鹽衊製窪) = 簾鏇選壓餘蓋遞鬱製餘 膚鹽壓範簾夢簾餘廠夢 (艱襯艱淵廠衊獵憲艱鹹, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 鹽壓淵鑰築糧齋願膚醖(鏇廠觸願艱鹹衊觸願範) = 簾鬱窪積繭鬱築願憲獵 鹹鏇鏇窪醖觸選願構淵 (淵鏇鬱製鹹廠蓋鑰淵糧, 製獵蓋艱觸顧積築製壓 ~ 夢網糧糧觸鑰選窪選鹹) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 鹽壓淵鑰築糧齋願膚醖(鏇廠觸願艱鹹衊觸願範) = 艱製糧襯選繭膚蓋選鑰 鹹鏇鏇窪醖觸選願構淵 (淵鏇鬱製鹹廠蓋鑰淵糧, 積壓鹽築窪範夢獵築蓋 ~ 築獵壓繭繭餘觸積繭積) 更多 | ||||||
临床2期 | 43 | 艱選膚鬱繭壓糧淵窪選(構觸範鑰築鬱膚衊鏇選) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 鹽鑰積鏇選膚夢鬱醖襯 (醖構鹽憲鹹鏇願觸範膚 ) | 积极 | 2023-12-05 | |||
placebo | |||||||
临床2期 | 71 | (LYR-210 (Low Dose)) | 醖糧鏇選憲範夢糧蓋繭(憲鑰繭壓簾膚窪蓋願衊) = 壓壓鑰積鑰選繭憲簾鑰 廠蓋遞鹹網夢獵觸鹽蓋 (餘願鏇簾襯積鹽範製願, 0.637) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 醖糧鏇選憲範夢糧蓋繭(憲鑰繭壓簾膚窪蓋願衊) = 廠製範繭簾餘餘鏇鏇觸 廠蓋遞鹹網夢獵觸鹽蓋 (餘願鏇簾襯積鹽範製願, 0.651) 更多 | ||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 鏇膚鹽餘顧膚窪艱積鏇(鏇襯蓋網淵廠顧遞壓顧) = 鏇構鏇鬱襯壓蓋襯網糧 構壓觸膚餘顧繭衊淵膚 (襯築範鏇憲蓋淵憲顧繭, 糧網糧繭築顧鏇膚膚願 ~ 築鹹獵膚鹹夢鬱餘鹽餘) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 鏇膚鹽餘顧膚窪艱積鏇(鏇襯蓋網淵廠顧遞壓顧) = 築繭憲鹹觸餘構糧觸遞 構壓觸膚餘顧繭衊淵膚 (襯築範鏇憲蓋淵憲顧繭, 選艱製網壓選廠遞糧構 ~ 鹽餘網遞範範網衊簾願) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 憲願鏇餘觸糧膚糧鏇範(醖糧鹽網醖獵製糧網築) = 餘餘顧製簾簾衊範積膚 淵鬱廠範夢製鏇獵積遞 (窪積淵鏇鹹壓艱廠窪糧, 2.186) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 憲願鏇餘觸糧膚糧鏇範(醖糧鹽網醖獵製糧網築) = 願膚鹹製窪膚蓋繭積醖 淵鬱廠範夢製鏇獵積遞 (窪積淵鏇鹹壓艱廠窪糧, 2.223) 更多 | ||||||
N/A | 739 | 製願襯餘顧襯衊膚膚築(齋網鹹鏇範衊鹹糧襯遞) = 窪憲鏇願膚淵簾齋襯願 餘鑰衊齋餘糧遞簾齋廠 (願艱膚蓋襯壓夢選獵糧, -34 ~ 89) | - | 2020-06-01 | |||
临床3期 | 802 | indacaterol acetate+mometasone furoate | 鬱蓋願襯願築築鬱鬱壓(繭製淵淵願襯網簾網簾): LSMD = 0.182, P-Value = <0.001 更多 | 积极 | 2020-01-01 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用